Impaired cyclin D3 protein degradation contributes to trastuzumab resistance in HER2 positive breast cancer

Zhuo Wang, Haiqi Lu, Yiming Zhong, Lifeng Feng, Hongchuan Jin, Xian Wang · 2024

Read Impaired cyclin D3 protein degradation contributes to trastuzumab resistance in HER2 positive breast cancer by Zhuo Wang, Haiqi Lu, Yiming Zhong, Lifeng Feng, Hongchuan Jin, Xian Wang (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11531418.txt.

Description

As the first anti-HER2 targeted agent approved by FDA in 1998, Trastuzumab has significantly improved the outcome of patients with HER2 positive metastatic breast cancer. Unfortunately, resistance to trastuzumab is a severe obstacle to its therapeutic efficacy in clinical application, and its mechanism has not yet been fully elucidated.

Catalog record

CREATORZhuo Wang, Haiqi Lu, Yiming Zhong, Lifeng Feng, Hongchuan Jin, Xian Wang
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE46 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11531418

Browse the full library · About the Tower of Babel